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Human neutrophil elastase (HNE)' has been implicated in the pathogenesis of
a wide variety of human diseases (1). In the past, it was difficult to measure HNE
activity in vivo because the enzyme rapidly interacts with its major plasma
inhibitor, a, proteinase-inhibitor (2), which complexes and inactivates the free
enzyme with an estimated rate constant of association of 6.5 x 10'/M-s (3).
Recently, Weitz et al. (4) developed a sensitive assay to measure in vivo HNE
activity. This assay makes use of the capacity of HNE to cleave the Val (Aa2l)-
Glu (Aa22) bond at the NH2-terminal region ofthe Aa chain offibrinogen, thus
releasing the fibrinopeptide A-containing fragment Aal-21 . This peptide can
be measured in plasma by RIA and its level reflects in vivo HNE activity (4).
Usingthis assay, higher Aa1-21 levels were found in plasma ofcigarette smokers
than in plasma ofnonsmokers (5). Further, individuals with congenital deficiency
of a, proteinase-inhibitor had values of plasma Aal-21 considerably higher
than those in smokers (4). Increased Aal-21 levels in patients lacking antipro-
teinase were expected. However, the presence ofcirculating Aal-21 in individ-
uals with normal plasma concentrations of antiproteinase was puzzling given the
rapidity of the interaction between HNE and a, proteinase-inhibitor.
In vitro studiesofproteolysis by polymorphonuclear leukocytes (PMN) suggest
an explanation for the presence ofAal-21 in the plasma ofnormal individuals.
These studies show that enzymes released from stimulated PMN can degrade a
variety of susceptible macromolecular substrates in the presence of antiprotein-
ases(6-9), therebyraising thepossibility that cell-associatedproteinases are more
resistant to inhibition than are the free enzymes. To examine this hypothesis, we
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leukocytes; TBS, Tris-buffered saline; TIFPA, thrombin increasable fibronopeptide A immunoreac-
tivity.
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studied PMN-mediated fibrinogenolysis in the presence and absence of antipro-
teinases. We report here that stimulated human PMN, migrating through fibrin-
ogen-coated filters, demonstrate significant HNE-mediated fibrinogenolytic ac-
tivity in the presence of proteinase inhibitors as small as 20,000 mol wt. In
contrast, these same inhibitors completely block the fibrinogenolytic activity of
soluble purified HNE of the cell-free secretory material of stimulated PMN. Our
studies differ from previous ones in that: (a) we used PMN that had been
stimulated by a specific chemoattractant, FMLP; (b) we measured the activity of
a specific PMN enzyme (HNE) on a specific substrate (fibrinogen). This is in
contrast to previous workers who measured nonspecific substrate proteolysis that
may have resulted from the action of a variety of proteinases; and (c) we examined
the inhibitory effects of undiluted serum or plasma and excess concentrations of
antiproteinases on HNE activity.
Materials and Methods
Reagents.
￿
Purified HNE (10) and a specific polyclonal rabbit antibody to this enzyme
(11) were generous gifts of Drs. M. Brower and P. Harpel, Cornell Medical Center, New
York. Specific peptide chloromethyl ketone inhibitors of HNE and cathepsin G, MeO-
Suc-Ala2-Pro-Va1CH2Cl and Z-Gly-Leu-PheCH2C1, respectively, were from Enzyme Sys-
tems Products, Livermore, CA. FMLP was from Peninsula Laboratories, Inc., Belmont,
CA; a, proteinase-inhibitor was from Calbiochem-Behring Corp., San Diego, CA; and
soybean trypsin-inhibitor was from Sigma Chemical Co., St. Louis, MO. Poly-L-lysine
(mol wt, ^"70,000) was from Miles Laboratories Inc., Elkhart, IN; while Ficoll-400 and
Hypaque sodium were from Pharmacia Fine Chemicals, Piscataway, NJ.
Preparation of Fibrinogen Substrate.
￿
Human fibrinogen (grade L; Kabi Diagnostica,
Stockholm, Sweden) was rendered plasminogen-free by lysine Sepharose 4B affinity
chromatography in the presence of aprotinin (100 Kallikrein inhibition units, KIU/ml).
The fibrinogen was then further purified as previously described (12, 13). The clotting
ability of the purified material was 96%. The absence of plasminogen was confirmed by
incubating the fibrinogen for 48 h at 37° C with streptokinase (2 U/mg fibrinogen).
Electrophoresis of 50 Ag of unreduced sample on a 7.5% polyacrylamide gel revealed no
evidence of degradation.
For some experiments, fibrinogen was trace-labeled with 1251 by the solid-phase lacto-
peroxidase-glucose oxidase procedure (14) to a specific activity of 3.1 x 108 cpm/wg.
Unlabeled fibrinogen was mixed with the labeled material and the fibrinogen concentra-
tion was determined by measuring absorbance at 280 nm, using an extinction coefficient
of 1 .55.
Sartorius cellulose nitrate filters (Vanguard International Inc., Neptune, NJ) of 13-mm
diameter and 3-,um pore size were placed in 16-mm wells of tissue culture plates (Costar,
Cambridge, MA). The filters were incubated with 500 ul of 0.1 M NaCl buffered with
0.05 M Tris-HCI, pH 7.4 (TBS), containing 50 jig/Ml poly-L-lysine for 30 min at 23°C
with constant agitation . After washing with 500,u] of TBS three times, the poly-L-lysine-
coated filters were incubated with 0.5 mg of fibrinogen suspended in 500 A1 of TBS for
18 h at 23°C with constant agitation. The filters were then washed with 500 Al of TBS
three times, air dried for I h, mounted on modified chemotactic chambers (Adaps Inc.,
Dedham, MA), and used within 24 h. Each filter was coated with ^-95 ,ug of fibrinogen as
determined from the amount of radiolabeled fibrinogen bound per filter and the specific
activity of the tracer. There was little variation in amount of fibrinogen bound per filter
(95 ± 4 ug) among different batches of filters.
PMN Lysates and Supernatants.
￿
PMN were isolated from heparinized venous blood
obtained from normal volunteers by discontinuous Ficoll-Hypaque gradient (15). Unless
otherwise specified, all experiments were carried out in HBSS containing I mg/ml BSA.
For some studies however, the cells were directly suspended in undiluted human citrated1838
￿
NEUTROPHIL-MEDIATED FIBRINOGENOLYSIS
plasma (harvested from blood anticoagulated with 9:1 vol/vol, 3.8% trisodium citrate or
in plasma-derived serum (prepared by CaC12 addition to citrated plasma at a final calcium
concentration of 30 mM).
Cell-free lysates were prepared by freezing and thawing PMN (6.7 x 105 cells/ml HBSS)
eight times and removing the cellular debris by centrifugation at 3,000 g for 15 min at
4°C. Supernatants of FMLP-stimulated PMN were obtained by incubating PMN (6.7 x
105/ml HBSS) with FMLP (10-7 M) for 60 min at 37°C, removing the cells by centrifu-
gation at 3,000 g for 15 min at 4°C, and carefully collecting the supernatant and storing
it at 4°C until used in an experiment later the same day.
Rabbit anti-HNE IgG or control IgG was isolated and coupled to activated CH-
Sepharose 4B (Pharmacia Fine Chemicals) as previously described (4). Sepharose 4B (I
ml of a 50% suspension) bearing control or anti-HNE IgG and PMN lysates (0.5 ml) or
supernatants of FMLP-stimulated PMN (0.5 ml) were mixed for 30 min at room temper-
ature. After centrifugation, the HNE concentration in each supernatant was determined
by measuring hydrolysis of MeO-Suc-Ala2-Pro-ValAFC (Enzyme Systems Products), a
synthetic HNE substrate, and comparing this with that produced by known concentrations
of the purified enzyme. The HNE concentration in the lysates was 1 .8,ug/ml, while that
in the supernatants of FMLP-stimulated PMN was 0 .3 Ag/ml both before and after
absorption with control IgG. In contrast, after immunoabsorption with anti-HNE IgG
there was no measurable enzyme activity (<2 ng/ml) in either solution.
Assessment of Fibrinogenolysis.
￿
Chemotactic chambers fitted with fibrinogen-coated
filters were suspended in 16-mm tissue culture wells. In cell-free experiments, one of the
following substances was added to both the compartment above (0.27 ml) and below (1 .23
ml) the fitters and the chambers were then incubated at 37 ° C in a humidified 5% C02
incubator for 60 min: buffer; purified HNE (1-90 nM); PMN lysates; FMLP-stimulated
PMN supernatants; HNE-immunodepleted PMN lysates; or HNE-immunodepleted,
FMLP-stimulated PMN supernatants. In parallel experiments, the above assays were
performed with one ofthe following additions: 1 .0% plasma, 1 .0% plasma-derived serum,
a, proteinase-inhibitor (0 .03 mM), soybean trypsin-inhibitor (0 .3 mM), McO-Suc-Ala2-
Pro-ValCH2Cl (0.01 mM) or Z-Gly-Leu-PheCH2Cl (0.1 mM). In every case, 1.5 ml of
lysate from 106 PMN or 1.5 ml of supernatant of 106 FMLP-treated PMN was incubated
with each filter.
HNE activity was quantified by measuring Aal-21 release from the fibrinogen-coated
filters. 50-,uI aliquots were removed from both the upper and lower wells of each chamber
at 0, 30, and 60 min intervals from the time at which the test solution was added to the
filters. In some instances, an additional 5-Al aliquot was sampled as just described to
determine the release of '25I-labeled fibrinogen degradation products. Samples (50 I1) for
Aa1-21 analysis were incubated with 150 PI ethanol on ice for 30 min, followed by rapid
centrifugation (15,000g for 3 min) to precipitate any fibrinogen or high molecular weight
degradation products. The ethanol supernatants were collected, evaporated to dryness,
and reconstituted to their original volume with distilled water as previously described (4).
Release of "'I-labeled fibrinogen degradation products was determined by counting the
aliquots for 1 min on a Rackgamma counter (model 1270; LKB Instruments, Inc.,
Gaithersburg, MD). Aa1-21 concentrations were determined by RIA of thrombin increas-
able fibrinopeptide A immunoreactivity (TIFPA) as previously described (4). That TIFPA
immunoreactivity reflects free Aal-21 was confirmed by HPLC analysis of selected
samples and the demonstration that immunoreactive fractions coeluted with synthetic
Aal-21 (4).
Experiments with intact neutrophils were performed as above but with the following
differences: 106 PMN suspended in 0.27 ml of buffer were added above the fibrinogen-
coated filters and 10-' M FMLP was used below the filter as a chemoattractant. PMN
were allowed to migrate through the filters for 60 min at 37°C. a, proteinase-inhibitor,
soybean trypsin-inhibitor, MeO-Suc-Ala2-Pro-ValCH2Cl, and Z-Gly-Leu-PheCH2Cl were
added to the solutions on both sidesofthe filter as described above. In otherexperiments,
the PMN and FMLP were suspended in 100% plasma or 100% plasma-derived serum to
determine the effects of these substances on HNE activity. As controls, fibrinogen-coated400-
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filters were incubated with unstimulated PMN or with 10-7 M FMLP alone. All experi-
ments were performed in triplicate.
Chemotaxis Assays.
￿
Filters were removed from the chemotaxis chambers at the end of
the assay and stained as described by Wilkinson (16). PMN chemotaxis was assessed by
the leading front method (17). For each filter, the farthest distance at which two or more
cells had migrated was measured in five x 400 fields in triplicate samples and the mean
was determined.
600-
Results
HNE-mediated Fibrinogenolysis.
￿
In evaluating the system used in this study, a
number ofpreliminary experiments were performed. The sensitivity ofthe assay
system was investigated by incubating the fibrinogen-coated filters with increas-
ing concentrations of HNE. This resulted in dose-dependent release of Aal-21
from fibrinogen (Fig. 1). When the molar ratio ofHNE to fibrinogen was 2_0.25,
all of the available peptide (2 mol/mol fibrinogen) was released. Similarly, HNE
produced concentration-dependent release of 125Mabeled fibrinogen degrada-
tion products (Fig. 2). Release of I25I-labeled fibrinogen degradation products
correlated with Aal-21 release, but was not used as a specific measure of HNE
activity.
Although quantitative release of Aal-21 from fibrinogen coating the filters
was effected by molar ratios ofenzyme to substrate exceeding 0.25, quantitative
peptide release from fibrinogen free in solution occurs at molar ratios of 0.025
or less (4). This discrepancy may be due to the relative inaccessibility of the
Aa21-22 bond to HNE when the fibrinogen is immobilized on the filters.
Alternatively, the negatively charged cellulose nitrate filters may adsorb the
strongly cationic enzyme, thereby reducing the amount of HNE that is free to
degrade fibrinogen.
There was negligible Aal-21 release when the fibrinogen-coated filters were
incubated with buffer alone or with FMLP (Table I). Unstimulated PMN in
contact with fibrinogen-coated filters released 30.3 pmol ofAal-21, suggesting
that interaction ofthe cells with the substrate is in itself astimulus for some HNE
release. When PMN above the fibrinogen-coated filters were stimulated to
migrate through the filter by 10-7 M FMLP on the opposite side, however,
-2
0
FIGURE 1 . HNE-mediated Aal-21 re-
lease from fibrinogen-coated filters. Fibrin-
ogen-coated filters were incubated with in-
creasing concentrations of purified HNE
(1-90nM) for 60 min at 37°C and Aal-21
release was measured by RIA. The results
shown are the mean of two separate exper-
iments.1840
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Addition
Buffer alone
FMLP alone
PMN alone
PMN + FMLP
1
￿
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TABLE I
Aal-21 Releasefrom Fibrinogen-coatedFilters
FIGURE 2. HNE-mediated 1251-fi-
brino en hydrolysis. Filters coated
with 251-fibrinogen were incubated
with increasing concentrations ofpu-
rified HNE (1-90 nM) for 60 min at
37°C and release of 1251-labeled fi-
brinogen degradation products was
determined. A maximum of 59% of
the 1251-fibrinogen coating thefilters
was hydrolyzed by HNE. The results
shown are the mean of two separate
experiments.
Aal-21 release at 60 min
incubation
pmol
0.2 ± 0.01
0.1 ± 0.01
30.3 t 8.6
161.3 t 18.1
Theresults shownarethe means ± SD from threeseparate experiments.
peptide release was increased more than fivefold, consistent with enhanced HNE
release after chemoattractant stimulation ofthe cells. Thus, unstimulated PMN
in contact with the fibrinogen-coated filters produced the same Aal-21 release
as did 2 nM purified HNE (Fig. 1), whereas peptide release by FMLP-stimulated
PMN was equivalent to that produced by 11 nM HNE.
Proteinase Inhibitors Block Fibrinogenolysis by Supernatants of FMLP-stimulated
PMN. We compared therelative abilityofa varietyofantiproteinases (including
a, proteinase-inhibitor, soybean trypsin-inhibitor, McO-Suc-Ala2-Pro-Val-
CH2C1, and Z-Gly-Leu-PheCH2Cl) to inhibit the fibrinogenolytic activity of the
enzymes present in the supernatants of FMLP-stimulated PMN with the ability
ofthese agents to regulate fibrinogenolysis by intact PMN. The inhibitory effect
ofplasma and plasma-derived serum also was investigated. Plasma-derived serum
was used to examine the possibility that the fibrinogen contained in plasma was
providing additional substrate for the PMN proteinases. First we established that
HNE was secreted by FMLP-stimulated PMN and confirmed its role in producing
Aal-21 release. Supernatants from FMLP-stimulated PMN incubated with
fibrinogen-coated filters for 60 min released 151.0 pmol of Aal-21 (Table 11).WEITZ ET AL.
TABLE II
Effect ofInhibitors on Aal-21 Release by Supernatants of
FMLP-stimulated PMN
The resultsshown are the means ± SD from twoseparate experiments.
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The release of peptide by the free enzyme recovered in the supernatants of
FMLP-stimulated cells was inhibited >99% by a, proteinase-inhibitor, soybean
trypsin-inhibitor, 1 % plasma and 1 % plasma-derived serum (Table II). When
fibrinogenolysis was assayed by measuring release of '25I-labeled fibrinogen
degradation products, similar results were obtained. Once again, release was
completely blocked by a, proteinase-inhibitor, soybean trypsin-inhibitor,
plasma, and plasma-derived serum (data not shown). Aal-21 release was abol-
ished by MeO-Suc-Ala2-Pro-VaICH2C1, a specific peptide chloromethyl ketone
inhibitor of HNE (18), whereas Z-Gly-Leu-PheCH2C1, a cathepsin G inhibitor
(18), had no effect. Further confirmation that HNE was the enzyme responsible
for the Aal-21 release came from the demonstration that supernatants immu-
nodepleted of HNE produced minimal peptide release (0.1 pmol). Thus, HNE
was the enzyme in the supernatants of FMLP-stimulated PMN that promoted
Aa1-21 release and free HNE in these solutions was readily inhibited by several
antiproteinases.
HNE Is the Major Fibrinogenolytic Enzyme Contained in PMN.
￿
To determine
whether the proteinases released from PMN after FMLP stimulation are repre-
sentative of the major fibrinogenolytic enzymes contained within these cells, the
experiments were repeated using PMN lysates (Table III). Release of Aal-21
by the lysates was completely inhibited by plasma, plasma-derived serum, a,
proteinase-inhibitor, and soybean trypsin-inhibitor. HNE was the enzyme re-
sponsible for peptide release since Aal-21 release was completely inhibited by
MeO-Suc-Ala2-Pro-Va1CH2Cl, and lysates immunodepleted of HNE produced
negligible peptide release (0 .9 pmol). In contrast, the cathepsin G inhibitor, Z-
Gly-Leu-PheCH2C1, had no effect.
When HNE concentration was measured by amidolytic activity, the lysates
contained considerably more enzyme than did the supernatants of FMLP-treated
PMN, and therefore, exerted greater fibrinogenolytic activity. These findings
confirm previous reports that FMLP is a weak stimulus for HNE release from
PMN (19).
All the inhibitors (1% plasma, 1 % plasma-derived serum, a, proteinase-
inhibitor, soybean trypsin-inhibitor, and MeO-Suc-Ala2-Pro-Va1CH2C1) blocked
99% of the activity of free HNE in the FMLP-stimulated PMN supernatants
Inhibitor Aa1-21 releaseat 60
min incubation
pmol
None 151.0 t 10.6
Z-Gly-Leu-PheCH2Cl (0.1 MM) 162.3 t 15.2
Plasma (I %) 0.1 t 0.01
Serum (1%) 1.5 t 0.9
a, Proteinase-inhibitor (0.03 mM) 0.1 t 0.01
Soybean trypsin-inhibitor (0.3 mM) 0.9 t 0.1
Me0-Suc-Ala2-Pro-Va1CH2Cl (0.01 mM) 0.1 t 0.011842 NEUTROPHIL-MEDIATED FIBRINOGENOLYSIS
TABLE III
Effect ofInhibitors on Aal-21 Releasefrom Fibrinogen-coated Filters
Produced by PMNLysates
Inhibitor
TABLE IV
None
Inhibitors at theconcentrations indicatedwere added to lysates from 106
PMN and incubated with fibrinogen-coated filters for 60 min at 37°C.
Aal-21 wasassayed as described in Materialsand Methods. 0.03 mM a,-
proteinase inhibitor (1 .35 mg/100 ml) is within the physiologic range of
this inhibitor in normal human plasma. The resultsshown are the means
± SD from twoseparate experiments.
Effect of Inhibitors on Aal-21 Release by FMLP-stimulated PMN
Aa1-21 releaseat
￿
Inhibition 60 min incubation
pmol
161.3 t 18.1
￿
-
Inhibitors at the concentrations indicated were present in both the upper and
lower chambers of chemotaxis apparatus. 106 PMN were used in each assay.
Note that plasma, and plasma derived serum were used in 100 fold excess of the
amountsrequired to inhibit 99.5% of all the elastase activity secreted by FMLP
stimulated PMN (Table II), or present in lysates of 106 PMN (Table III). The
results shownare the means and S.D. from three separate experiments.
(Table II) and >99.5% of the activity in the PMN lysates (Table III). This
confirms that the inhibitors were used in sufficient concentrations to block the
entire HNE content ofall the PMN used in the assay.
PMN-mediated Fibrinogenolysis is Incompletely Blocked by High Molecular Weight
Elastase Inhibitors. Given the >99% inhibition of soluble HNE by 1% plasma,
1% plasma-derived serum, a, proteinase-inhibitor, and soybean trypsin-inhibi-
tor, we tested the ability ofthese agents to regulate PMN-mediated fibrinogen-
olysis. In contrast to their effects on soluble HNE, these inhibitors were signifi-
cantly less potent in blocking the fibrinogenolytic activity of PMN that were
stimulated by FMLP to migrate across fibrinogen-coated filters. Even in the
presence of undiluted plasma or plasma-derived serum there was incomplete
inhibition (85 and 81%, respectively) ofAa1-21 release (Table IV). Further, a1
proteinase-inhibitor and soybean trypsin-inhibitor, at concentrations that inhib-
Plasma (100%) 24.6±8.4 8513
Serum(100%) 30.9±2.0 81±1
a, Proteinase-inhibitor (0.03 mM) 19.3±10.2 88±4
Soybean trypsin-inhibitor (0.3 mM) 17.2±5.8 89t 1
MeO-Suc-Ala2-Pro-VaICH2Cl (0.01 MM) 0.5 t0.2 >99
Inhibitor Aal-21 releaseat 60
min incubation
pmol
None 550.9 t 18.6
Z-Gly-Leu-PheCH2Cl (0.1 MM) 561.3 ± 20.2
Plasma (1%) 0.9 t 0.1
Serum (I%) 1 .1 t 0.2
a, Proteinase-inhibitor (0.03 mM) 0.1 ± 0.01
Soybean trypsin-inhibitor (0.3 mM) 2.1 ± 0.3
MeO-Suc-Ala2-Pro-VaICH2Cl (0.01 MM) 0.1 t 0.01WEITZ ET AL.
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FIGURE 3 . Inhibition of PMN-medi-
ated "'I-fibrinogen hydrolysis by anti-
proteinases . PMN (106/filter) were stim-
ulated bFMLP (10-' M) to migrate
across "11-fibrinogen-coated filters in
the presence andabsence of antiprotein-
ases . In buffer alone, the FMLP-stimu-
lated PMN produced the same '25I-fi-
brinogen hydrolysis as did 11 nM puri-
fied HNE, and this is shown for compar-
ison . The percent residual activity after
the addition of a, proteinase-inhibitor
(a,PI) (0.03 mM), plasma or serum
(100%), and AAPVCK (MeO-Suc-Ala2-
Pro-Va1CH2Cl, 0.01 mM) is indicated .
The bars represent the mean of three
separate experiments (eachdone in trip-
licate), while the lines above the bars
representthe standard deviations .
ited 99% of theHNE activity in lysates of all the PMN added to the assays (Table
III), did not completely block Aal-21 release (88 and 89%, respectively) by the
migrating cells . In contrast, peptide release by migrating PMN was completely
abolished by MeO-Suc-Ala2-Pro-ValCH2C1 .
Quantitatively similar results were obtained when fibrinogenolytic activity was
monitored by measuring release of 121I-labeled fibrinogen degradation products
(Fig. 3) . Again, the activity was incompletely blocked by 100% plasma, 100%
plasma-derived serum, or a, proteinase inhibitor, but incompletely blocked by
MeO-Suc-Ala2-Pro-ValCH2Cl.
The data given in Fig. 3 permit a quantitative evaluation of the ratio of
proteinase inhibitors toHNE in the studies reported here. 11 pmol/ml ofpurified
HNE released as much ' 251-fibrinogen degradation product from the filters as
106 chemotaxing PMN. The concentrations of a, proteinase- and soybean
trypsin-inhibitors used in this experiment and in those reported in Table IV
were in 3,000- and 30,000-fold molar excess of the amount ofHNE required to
give the fibrinogenolysis observed . Despite this vast excess of inhibitors they
effected incomplete inhibition of PMN-mediated fibrinogenolysis . In contrast,
MeO-Suc-Ala2-Pro-ValCH2Cl, which was present in only 1,000-fold molar excess
of HNE (Fig. 3 and Table 4), gave >99% inhibition of PMN-mediated fibrino-
genolysis .
Inactivation of a, proteinase-inhibitor by PMN-derived oxidants is one mech-
anism by which HNE released from the migrating PMN could remain active in
the presence of plasma or serum containing this antiproteinase (20-23) . How-
ever, this mechanism does not explain the incomplete inhibition of fibrinogen-
olytic activity by soybean trypsin-inhibitor, which is resistant to oxidant inacti-
vation . Furthermore, chemoattractants such as FMLP are weak stimulators of
oxidant release from PMN (24) . Therefore, oxidative inactivation of plasma
proteinase inhibitors is unlikely to be the mechanism by which HNE escapes
regulation in this experimental system . These studies thus indicate that PMN-
mediated fibrinogenolysis can occur in thepresence ofphysiologic concentrations
ofantiproteinases and that only the low molecular weight chloromethyl ketone-
inhibitor ofHNE can totally inhibit PMN-mediated fibrinogenolysis .1844 NEUTROPHIL-MEDIATED FIBRINOGENOLYSIS
TABLE V
Effect ofAntiproteinases on PMNMigration through
Fibrinogen-coated Filters
Inhibitor
None
Plasma (100%)
Serum (100%)
a, Proteinase-inhibitor (0.03 mM)
MeO-Suc-Ala2-Pro-ValCH2Cl (0.01 MM)
Discussion
PMN migration
Jam
123 t8
128 ± 17
144±8
144t8
127±6
Each result represents the mean ± SD of five separate fields measured in
three replicate filters.
To investigate whether the mechanism by which MeO-Suc-Ala2-Pro-ValCH2C1
inhibited PMN-mediated fibrinogenolysis was through uptake and inhibition of
intracellular HNE, we performed the following experiments. First, lysates were
prepared from 106 PMNs that had been preincubated with 0.01 mM McO-Suc-
Ala2-Pro-ValCH2C1 for 60 min at 37°C and then washed extensively before
preparation of the lysates. Incubation of these lysates with fibrinogen-coated
filters resulted in similar Aa1-21 release as produced by PMN lysates prepared
from cells not previously exposed to the HNE inhibitor (558.2 pmol and 550.9
pmol, respectively). Second, FMLP stimulation of PMN that had been preincu-
bated for 60 min with 0.01 mM MeO-Suc-Ala2-Pro-ValCH2C1 resulted in similar
Aa1-21 release from fibrinogen-coated filters as occurred with PMN not previ-
ously exposed to the peptide chloromethyl ketone-inhibitor (148.2 pmol and
161 .2 pmol, respectively). These experiments thus indicate that McO-Suc-Ala2-
Pro-VaICH2C1 does not significantly inhibit intracellular HNE.
Inhibitors ofPMN Fibrinogenolysis Do Not AlterPMN Chemotaxis.
￿
None of the
inhibitors (including serum or plasma) altered PMN chemotaxis in response to
FMLP (Table V), thus excluding the possibility that these agents exert their
effects by impairing PMN migration. Since MeO-Suc-Ala2-Pro-Va1CH2C1 com-
pletely inhibited HNEactivity (as measured byAa1-21 release) without affecting
PMN chemotaxis, HNE activity is nota requirement for PMN chemotaxis in this
system.
Adherence of macrophages to a ligand-coated surface results in such close
apposition of the cells to the surface that molecules as small as 50,000 mol wt
cannot penetrate into this space. This led Wright and Silverstein (25) to propose
that macrophage secretory products (such as proteolytic enzymes or H202)
released at the cell-surface interface would be protected from the effects of
inhibitors such as a2 macroglobulin, at proteinase-inhibitor, or catalase. The
work ofBaron et al. (26)suggests that a similarsituation prevailswhen osteoclasts
degrade bone. The osteoclasts form a tight seal against the bone, acidify the
space between their membrane and the bone, and release matrix-degrading
enzymes into this space. The net effect is bone resorption that is strictly confinedWEITZ ET AL.
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to the area directly beneath the osteoclast, and is unaffected by the neutral pH
and proteinase inhibitors ofthe extracellular fluids.
In the studies reported here we have tested whether one PMN secretory
product, HNE, also is protected from inhibition by plasma antiproteinases when
PMN bind to, and migrate on, a fibrinogen-coated surface. Our results show
that very low concentrations (1%) of plasma and serum or macromolecular
proteinase inhibitors (a, proteinase inhibitor and soybean trypsin-inhibitor)
completely blocked fibrinogenolysis mediated by soluble HNE present in PMN
lysates or secreted by PMN stimulated with a chemoattractant (Tables II and
III), but that the considerably higher concentrations of antiproteinases present
in undiluted serum or plasma incompletely blocked (81-85%) fibrinogenolysis
mediated by PMN migrating in response to a chemoattractant. It is important to
note that the total amount of Aacl-21 released by the lysates of 106 PMN was
3.4-fold greater than that produced by FMLP-stimulated PMN (550 pmol [Table
111, line 1] vs. 151-161 pmol [Tables II and IV, line I] Aal-21 released,
respectively); and that the total amount of enzyme in 106 PMN was inhibited
>99% by the proteinase inhibitors present in 1% plasma or 1% plasma-derived
serum. Thus, at minimum, the amount of HNE inhibitor in the 100% plasma or
100% plasma-derived serum used to block HNE activity of chemotaxing PMN
(Fig. 3 and Table IV) was 340-fold in excess of the amount required to inhibit
the total content ofthe HNE in the PMN used in these experiments. As indicated
in Results (Fig. 3), we estimate that the a, proteinase- and soybean trypsin-
inhibitors were in 3,000- and 30,000-fold molar excess, respectively, of the
amount ofHNE released by 106 chemotaxing HNE. Thus, it is evident that the
macromolecular inhibitors used were present in sufficient concentrations and
amounts to block all the HNE contained in the PMN used in these experiments.
In contrast, MeO-Suc-Ala2-Pro-Va1CH2C1, a specific low molecular weight
inhibitor of HNE (18), used at a concentration that was only 1,000-fold in molar
excess of the HNE secreted by chemotaxing PMN, blocked >99% of the
fibrinogenolysis mediated by the PMN. MeO-Suc-Ala2-Pro-Va1CH2C1 did not
affect intracellular HNE, HNE secretion from the PMN, or PMN migration in
response to thechemoattractant (Table V). These findings providecircumstantial
evidence in support of the hypothesis that PMN migrating on fibrinogen-coated
substrate occlude a significant portion of their zone ofcontact with the substrate
from macromolecular proteinase inhibitors in plasma.
Casual inspection suggests that the findings of Chapman and Stone (9) are in
conflict with those reported here. They demonstrated that elastin proteolysis by
PMN is completely inhibited in the presence of 10% serum. However, the PMN
used in their studies were not stimulated by chemoattractants and hence would
differ from those used in our investigations in two important ways. First, since
FMLP is a secretagogue for PMN, unstimulated PMN release less HNE than do
stimulated cells. Second, and perhaps more importantly, FMLP causes quantita-
tive and qualitative alterations in the expression and function of several PMN
membrane receptors (27, 28).
Stimulation of PMN with FMLP or C5a produces a five- to sixfold increase in
receptors that bind the C3b and C3bi cleavage products ofthe third component
of complement (27). In addition, chemoattractant-stimulated PMN exhibit a1846
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qualitative change in the activity oftheir fibronectin receptors (28). When PMN
are stimulated by either chemoattractants or fibronectin they bind complement-
coated particles via their Cab or C3bi receptors but do not ingest them. When
stimulated by both chemoattractants and fibronectin, however, PMN bind and
phagocytose C3b and C3bi coated particles (Pommier, C. G., and E. Brown,
personal communication). Thus, ligation ofreceptors for chemoattractants func-
tionally "activates" PMN fibronectin receptors and ligation offibronectin recep-
tors on these PMN functionally activates their complement receptors. Both
fibronectin (29, 30) and C3bi (31, 32) contain the Arg-Gly-Asp (RGD) amino
acid sequence. The RGD sequences in these molecules are ligands for the
corresponding receptors on leukocytes (32, 33). Fibrinogen also contains RGD
sequences and these mediate fibrinogen binding to platelets (34, 35) and perhaps
to leukocytes (36). It is possible, therefore, that the RGD sequences on substrate-
adherent fibrinogen may act as ligands for PMN receptors, e.g., the fibronectin
and C3bi receptors (CR3). In the presence ofa chemoattractant, ligand binding
may result in receptor activation, thereby leading to close apposition of cells to
substrate. This would result in the formation of a protected microenvironment
thatexcludes macromolecular proteinase inhibitors similar to thatwhich develops
when macrophages interact with a C3bi-coated surface (25).
The results of these studies are consistent with the hypothesis that HNE
escapes regulation in vivo because close contact between migrating PMN and
fibrinogen prevents antiproteinase access to the enzyme. Further, these findings
may provide an important link in understanding why Aal-21 is found in the
plasma of normal individuals and why elevated levels of this peptide are found
in the plasma ofcigarette smokers. Each day ^-109 PMN (37) emigrate from the
vascular compartment into the extravascular tissues. PMN move across endothe-
lial cell monolayers only when stimulated by a chemotactic gradient (38). Such
gradients may be generated under physiological conditions by bacteria in the
intestinal tract and by the secretion of LTB4 by macrophages (39) in response to
a variety ofstimuli. For the reason outlinedabove, a low level offibrinogenolysis
maythus be aninescapableconsequence ofPMN emigrationfromthe vasculature
in response to many environmental and microbial stimuli.
Cigarette smoking mayamplify PMN emigration from the vasculature into the
lungs. The peripheral leukocyte count is elevated in cigarette smokers (40),
cigarette smoking delays PMN transit through the pulmonary circulation (41),
and increased numbers of PMN are recovered in the bronchial lavage fluid of
smokers (42). The mechanism for PMN attraction into the lungs is unknown but
macrophage-derived chemoattractants (43, 44) and secretory components (45),
nicotine (46), or complement components (47) have been implicated. The ele-
vated plasma Aal-21 levels in cigarette smokers may reflect the increase in
PMN traffic through the lungs. In addition to fibrinogen proteolysis, proteinases
released from PMN migrating through the lungs also may degrade components
of the pulmonary interstitium, thereby explaining why cigarette smoking is the
major risk factor for the development ofchronic lung disease (48).Plasma levels of the HNE-derived fibrinopeptide Aal-21 reflect in vivo
enzyme activity. To provide a possible explanation for the presence of circulating
Aal-21 in individuals with normal plasma antiproteinase concentrations we
investigated whether PMN-associated HNE is more resistant to inhibition than
the free enzyme. PMN were stimulated to migrate across ' 251-fibrinogen-coated
nitrocellulose filters in response to 10-7 M FMLP, and the extent of fibrinogen-
olysis was determined by measuring release of Aal-21 and '251-labeled fibrino-
gen degradation products. The fibrinogenolytic activity of migrating PMN was
then compared with that of free HNE present in PMN lysates or secreted by
PMN stimulated with FMLP. Whereas the fibrinogenolytic activity of soluble
HNE was completely inhibited by low concentrations (1%) of plasma or serum
and macromolecular antiproteinase (a, proteinase-inhibitor and soybean tryp-
sin-inhibitor), even in the presence of undiluted plasma or serum the activity of
the migrating PMN was incompletely blocked (81-85%). Further, concentrations
of a, proteinase-inhibitor and soybean trypsin-inhibitor that totally inhibited
free HNE activity also incompletely blocked (88-89%) the fibrinogenol
activity of migrating PMN, indicating that FMLP-stimulated PMN demonstrate
significant fibrinogenolytic activity in the presence of antiproteinases as small as
20,000 mol wt. A specific low molecular weight HNE inhibitor (MeO-Suc-Ala2-
Pro-VaICH2Cl), however, totally blocked PMN-mediated fibrinogenolysis with-
out affecting intracellular HNE activity, HNE secretion from PMN, or PMN
migration in response to FMLP. These findings support the hypothesis that
PMN migrating on a fibrinogen-coated surface form zones of close contact with
fibrinogen, thus preventing access of plasma antiproteinases to HNE released at
the cell-substrate interface. The occurrence of this phenomenon in vivo would
explain the presence of circulating Aal-21 in individuals with normal antipro-
teinase concentrat
WEITZ ET AL
￿
1847
Summary
The authors thank Drs. J. Hirsh and S. D. Wright for their helpful comments, Drs. E. J.
Brown and S. D. Wright for their permission to cite unpublished work, and S. Crnic for
preparing this manuscript.
Receivedfor publication 5 May 1987 and in revisedform 13 August 1987.
References
1 . Janoff, A. 1985. Elastase in tissue injury. Annu. Rev. Med. 36:207.
2. Travis, J., and G. S. Salveson. 1983. Human plasma proteinase inhibitors. Annu. Rev.
Biochem. 52:655.
3. Beatty, J., J. Bieth, and J. Travis. 1980. Kinetics of association of serine proteinases
with native and oxidized alpha-l-proteinase inhibitor and alpha- I-antichymotrypsin.
J. Biol. Chem. 255:3931 .
4. Weitz, J. L, S. L. Landman, K. A. Crowley, S. Birken, and F. J. Morgan. 1986.
Development of an assay for in vivo neutrophil elastase activity. Increased elastase
activity in patients with alpha-l-proteinase inhibitor deficiency.J. Clin. Invest. 78 :155.
5. Weitz, J. L, K. A . Crowley, S. L. Landman, B. 1. Lipman, andJ. Yu. 1987. Increased
human neutrophil elastase activity in cigarette smokers. Ann. Intern. Med. In press.
6. Johnson, K. J., and J. Varani. 1981 . Substrate hydrolysis by immune complex-1848
￿
NEUTROPHIL-MEDIATED FIBRINOGENOLYSIS
activated neutrophils: effect of physical presentation of complexes and protease
inhibitors.J. Immunol. 172:1875.
7, Campbell, E. J., R. M. Senior, J. A. McDonald, and D. L. Cox. 1982 . Proteolysis by
neutrophils. Relative importance of cell-substrate contact and oxidative i
of proteinase inhibitors in vitro. f. Clin. Invest. 70:845.
8. Weirs, S. J., J. T. Curnutte, and S. Regiani. 1986. Neutrophil-mediated solubilization
of the subenclothelial matrix: oxidative and nonoxiclative mechanisms of proteolysis
used by normal and chronic granulomatous disease phagocytes.J. Immunol. 136:636.
9. Chapman, H. A., Jr., and 0. L. Stone. 1984. Comparison of live human neutrophil
and alveolar macrophage elastolytic activity in vitro. J. Glin. Invest. 74:1693.
10 . Brower, M. S., and P. C. Harpel. 1982. Protedytic cleavage and inactivation of alpha-
2-plasmin inhibitorand C I inhibitor by human polymorphonuclear leukocyte elastase.
I Biol. Chem. 257:9849 .
It . Brower, M. S., and P. C. Harpel. 1983. Alpha-I-antitrypsin human leukocyte elastase
complexes in blood. Quantification by an enzyme-linked differential antibody im-
munosorbent assay and comparison with alpha-2-plasmin inhibitor-plasmin com-
plexes. Blood. 61 :842.
fibber, B. A. K., D. G. Deutsch, and E. T. Mertz. 1974. Plasminogen. Methods
. 34A24.
13. Finlayson J. S. 1968. Chromatographic purification of fibrinogen. In Fibrinogen. K.
i, editor. Marcel Dekker, Inc., New York. 39-59
rd, A. L., and Z. A. Cohn. 1972. The enzymatic iodination of the red cell
membrane. J. Cell Biol. 55:390.
15. English, D., and B. R. Andersen. 1974. Single-step separation of red blood cells,
granulocytes, and mononuclear leukocytes on discontinuous density gradients of
Ficoll-Hypaquej Immunot. Methods. 5:249.
16, Wilkinson, P. C. 1982. Chemotaxis and Inflammation. Churchill Livingstone, Inc.,
York. 201 .
nd, S. H ., and J. G, Hirsch. 1973. Leukocyte locomotion and chemotaxis. New
methods for evaluation and demonstration of a cell-derived chemotactic factor. J.
Exp. Med. 137:387 .
18. Powers, J. C., B. F. Gupton, A. D. Honey, N. Nishino, and R. J. Whitley. 1977.
Specificity ofporcine pancreatic elastase, human leukocyte elastase and cathepsin G.
Lion with peptide chloromethyl ketones. Biochim. Biophys. Acta. 485:156.
19. Fittschen, C., R. A. Sandhaus, G. S. Worthen, and P. M. Henson. 1985. Human
neutrophils express elastase in response to chemotactic concentrations of FMLP. Fed.
Proc. 44:1919a. (Abstr.)
20. Weirs, S. J., and S. Regiani. 1984, Neutrophils degrade subenclothelial matrices in
the presence of alpha-I-proteinase inhibitor. Cooperative use of lysosomal proteinases
and oxygen metabolites.J. Clin. Invest. 73:1297.
21 . Carp, H., and A. Janoff. 1980. Phagocyte-derived oxidants suppress the elastase-
inhibitory activity of alpha- I-protemase inhibitor in vitro.J. Glin. Invest. 66:987.
22. Carp, H., and A. janoff. 1979. In vitro suppression of serum elastase-inhibitory
capacity by reactive oxygen species generated by phagocytosing polymorphonuclear
leukocytes. J. Glin. Invest. 63:793.
23 . Ossanna, P. J., S. T. Test, N. R. Matheson, S. Regiani, and S. J. Weirs. 1986 .
Oxidative regulation of neutrophil clastase-alpha-l-proteinase inhibitor interactions.
J. Glin. Invest. 77:1939.
21 Test, S. T, and S.I Weirs. 1984. Quantitative and temporal characterization of the
extracellular H202 pod generated by human neutrophils.J. Biol. Chem. 251399.WEITZ ET AL.
￿
1849
25. Wright, S. D., and S. C. Silverstein. 1984. Phagocytosing macrophages exclude
proteins from the zonesof contact with targets. Nature (Lond.). 309:359.
26. Baron, R., L. Ness, B. Rouvard, and P. J. Courtoy. 1985. Cell mediated extracellular
acidification and bone-resorption: evidence of a low pH in resorbing lacunae and
localization of a 100 kD lysosomal membrane protein at the osteoclast ruffled border.
J. Cell Biol. 101 :2210.
27. Berger, M ., J. O'Shea, A. S. Cross, T. M . Folks, T. M. Chused, E. J. Brown, and M.
M. Frank. 1984 . Human neutrophils increase expression of C3bi as well as Cab
receptors upon activation. J. Clin. Invest. 74:1566.
28. Pommier, C. G., J. O'Shea, T. Chused, K. Yancey, M. M . Frank, T. Takahashi, and
E. J. Brown. 1984. Studies on the fibronectin receptors of human peripheral blood
leukocytes. Morphologic and functional characterization. J. Exp. Med. 159:137.
29. Pierschbacher, M. D., E. G. Haymen, and E. Ruoslahti. 1983. Synthetic peptide with
cell attachment activity of fibronectin . Proc. Natl. Acad. Sci. USA. 80:1224.
30. Pierschbacher, M. D., and E. Ruoslahti. 1984. Cell attachment activity of fibronectin
can 'be duplicated by small synthetic fragments of the molecule. Nature (Lond.).
309:30.
31 . DeBruijn, M . H. L., and G. H. Fey. 1985. Human complement component C3:
cDNA coding sequence and derived primary structure. Proc. Natl. Acad. Sci. USA.
82:708.
32. Wright, S. D., and B. C. Meyer. 1985. Fibronectin receptor of human macrophages
recognizes the sequence Arg-Gly-Asp-Ser. J. Exp. Med. 162:762 .
33. Wright, S. D., P. A. Reddy, M. T. C. Jong, and B. W. Erickson. 1987. C3bi receptor
(complement receptor type 3) recognizes a region of complement protein C3 con-
taining the sequence Arg-Gly-Asp. Proc. Natl. Acad. Sci. USA. 84:1965.
34. Haverstick, D. M., J. F. Cowan, K. M. Yamada, and F. A. Santoro. 1985. Inhibition
of platelet adhesion to fibronectin, fibrinogen and von Willebrand factor substrates
by a synthetic tetrapeptide derived from the cell binding domain of fibronectin.
Blood. 66:946.
35. Gartner, T. K., and J. S. Bennett. 1985. The tetrapeptide analogue of the cell
attachment site of fibronectin inhibits platelet aggregation and fibrinogen binding to
activated platelets. J. Biol. Chem. 260:11891 .
36. Sherman, L. A., and J. Lee. 1977. Specific binding of soluble fibrin to macrophages.
J. Exp. Med. 145:76.
37 . Cronkite, E. P. 1979. Kinetics of granulopoiesis. Clin. Haematol. 8:351 .
38. Furie, M. B., B. L. Naprstek, and S. C. Silverstein. 1987 . Migration of neutrophils
across monolayers of cultured microvascular endothelial cells: an in vitro model of
leukocyte extravasation. J. Cell Sci. 38 :161 .
39. Scott, W. A., N. A. Pawlowski, H. W. Murray, M. Andreach, J. Zrike, and Z. A .
Cohn. 1982. Regulation of arachidonic acid metabolism by macrophage activation.
J. Exp. Med. 155:1148.
40. Galdston, M., E. L. Melnick, R. M. Goldring, V. Levyska, C. A. Curasi, and A. L.
Davis. 1977. Interaction of neutrophil elastase, serum trypsin inhibitory activity, and
smoking history as risk factors for chronic obstructive pulmonary disease in patients
with MM, MZ, and ZZ phenotypes for alpha- l-antitrypsin. Am. Rev. Respir. Dis.
116:837.
41 . MacNee, W., B. A. Martin, S. Tanco, A. Belzberg, B. J. Wiggs, and J. C. Hogg. 1987 .
Cigarette smoking delays polymorphonuclear leukocyte (PMN) transit through the
pulmonary circulation. Am. Rev. Respir. Dis. 135 :146a . (Abstr.)
42 . Hunninghake, G. W., and R. G. Crystal. 1983. Cigarette smoking and lung destruc-1850
￿
NEUTROPHIL-MEDIATED FIBRINOGENOLYSIS
rophils in the lungs of cigarette smokers. Am. Rev. Respi
G., J. Gadek, and R. Crystal. 1984. Human alveolar macrophage
neutrophil chemotactic factor: stimuli and partial characterization. J. Clin. Invest.
66:473.
44. Merrill, W. W., G. P. Naegel, R. A. Mathay, and H. Y. Reynolds. 1980. Alveolar
macrophage-derived chemotactic factor. Kinetics of in vitro production and partial
characterization. J. Clin. Invest. 65:268.
45. Cohen, A. B., D. E. Chenoweth, and T. E. Hugh. 1982. The release of elastase,
myeloperoxidase, and lysozyme from human alveolar macrophages. Am. Rev. Respir.
Dis. 126 :241 .
46. Totti, N., K. T. McCusker, E. J. Campbell, G. L. Griffen, and R. M. Senior. 1984.
Nicotine is chemotactic for neutrophils and enhances neutrophil responsiveness to
chemotactic peptides. Science (Wash. DC). 233:169.
47. Kazmierowski, J. A., J. 1 . Gallin, and H. Y. Reynolds. 1977 . Mechanism for the
inflammatory response in primate lungs.J. Clin. Invest. 5:273.
48. Department of Health and Human Services. 1984 . The health consequences of
smoking: chronic obstructive lung disease. A report of the Surgeon General. Rock-
ville, MD.